Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for postoperative hypothalamic obesity after craniopharyngioma resection
ChiCTR2400094933Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in hypothalamic obesity (HO) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Body weight. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on ChiCTR2400094933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094933.